Stock PFIZER PFIZER LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Pfizer Limited Bombay S.E.

Equities

PFIZER

INE182A01018

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:56 2024-06-03 am EDT 		5-day change 1st Jan Change
4,746 INR +3.17% Intraday chart for Pfizer Limited +5.62% +11.18%
May. 17 Pfizer Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
May. 17 Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2024, Payable on or Before September 6, 2024 CI

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 152,157 184,043 207,004 198,918 158,614 217,263 - -
Enterprise Value (EV) 1 152,157 184,043 207,004 198,918 158,614 191,909 217,263 217,263
P/E ratio 35.5 x 36.2 x 41.6 x 32.5 x 25.4 x 34.8 x 34.7 x 30.4 x
Yield 0.68% 0.25% 0.77% 0.8% 1.01% 1.07% 0.96% 1.12%
Capitalization / Revenue 7.31 x 8.55 x 9.25 x 7.62 x 6.54 x 8.75 x 9.14 x 8.27 x
EV / Revenue 7.31 x 8.55 x 9.25 x 7.62 x 6.54 x 8.75 x 9.14 x 8.27 x
EV / EBITDA 26.9 x 32.1 x 29.1 x 23.8 x 19.6 x 30.2 x 30.5 x 26.4 x
EV / FCF 163 x 60.1 x 50.5 x 23.8 x 54.6 x 43.2 x 30 x 47.7 x
FCF Yield 0.61% 1.66% 1.98% 4.19% 1.83% 2.31% 3.34% 2.1%
Price to Book 5.05 x 5.42 x 8.65 x 6.94 x 4.95 x 6.17 x 5.41 x 4.9 x
Nbr of stocks (in thousands) 45,748 45,748 45,748 45,748 45,748 45,748 - -
Reference price 2 3,326 4,023 4,525 4,348 3,467 4,749 4,749 4,749
Announcement Date 5/28/19 6/15/20 5/26/21 5/20/22 5/15/23 5/17/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 20,815 21,516 22,386 26,110 24,248 21,932 23,764 26,278
EBITDA 1 5,652 5,726 7,121 8,357 8,089 6,353 7,129 8,219
EBIT 1 4,938 4,693 6,027 7,207 7,034 5,730 6,476 8,093
Operating Margin 23.72% 21.81% 26.92% 27.6% 29.01% 26.13% 27.25% 30.8%
Earnings before Tax (EBT) 1 6,599 6,425 6,687 7,729 8,240 7,461 8,352 9,544
Net income 1 4,290 5,091 4,976 6,126 6,239 5,513 6,264 7,158
Net margin 20.61% 23.66% 22.23% 23.46% 25.73% 25.14% 26.36% 27.24%
EPS 2 93.78 111.3 108.8 133.9 136.4 120.5 136.9 156.5
Free Cash Flow 1 933.2 3,063 4,096 8,343 2,907 5,028 7,253 4,558
FCF margin 4.48% 14.24% 18.3% 31.95% 11.99% 22.85% 30.52% 17.35%
FCF Conversion (EBITDA) 16.51% 53.5% 57.52% 99.83% 35.94% 83.28% 101.74% 55.45%
FCF Conversion (Net income) 21.75% 60.16% 82.32% 136.2% 46.59% 100.26% 115.78% 63.68%
Dividend per Share 2 22.50 10.00 35.00 35.00 35.00 51.03 45.55 53.30
Announcement Date 5/28/19 6/15/20 5/26/21 5/20/22 5/15/23 5/17/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 5,935 5,348 7,492 6,363 6,759 5,497 5,929 6,375 6,218 5,726 5,314 5,786 6,031 5,526
EBITDA 1 1,968 1,257 2,857 1,894 1,952 1,654 1,918 2,317 2,034 1,819 1,107 1,560 1,841 1,622
EBIT - - - - - - - - - - - - - -
Operating Margin - - - - - - - - - - - - - -
Earnings before Tax (EBT) - - - - - - - - - - - - - -
Net income 1 1,412 1,006 1,999 1,430 1,439 1,258 325.5 3,111 - 1,296 935.3 1,200 1,458 1,352
Net margin 23.8% 18.8% 26.68% 22.47% 21.29% 22.89% 5.49% 48.8% - 22.64% 17.6% 20.75% 24.17% 24.47%
EPS - 21.98 - - - - - - - - - - 32.80 -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 2/5/21 5/26/21 7/28/21 11/3/21 2/3/22 5/20/22 8/5/22 11/11/22 2/9/23 5/15/23 8/11/23 - - -
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 933 3,063 4,096 8,343 2,907 5,028 7,253 4,558
ROE (net income / shareholders' equity) 15.1% 15.9% 17.2% 23.3% 20.6% 14.8% 16.5% 17.1%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 658.0 742.0 523.0 626.0 701.0 770.0 877.0 969.0
Cash Flow per Share - - - - - - - -
Capex 1 44.9 18.2 177 153 650 250 403 425
Capex / Sales 0.22% 0.08% 0.79% 0.59% 2.68% 1.14% 1.7% 1.62%
Announcement Date 5/28/19 6/15/20 5/26/21 5/20/22 5/15/23 5/17/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Pfizer Limited

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.63% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.29% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.45% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.38% 318B
ABBVIE INC. Stock AbbVie Inc.
+3.50% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.45% 240B
NOVARTIS AG Stock Novartis AG
+9.07% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+7.42% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PFIZER Stock
  4. PFIZER Stock
  5. Financials Pfizer Limited